310 related articles for article (PubMed ID: 25022595)
1. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
2. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.
Gisslén M; Hagberg L; Fuchs D; Norkrans G; Svennerholm B
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):291-5. PubMed ID: 9525428
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
[TBL] [Abstract][Full Text] [Related]
5. Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Cusini A; Vernazza PL; Yerly S; Decosterd LA; Ledergerber B; Fux CA; Rohrbach J; Widmer N; Hirschel B; Gaudenz R; Cavassini M; Klimkait T; Zenger F; Gutmann C; Opravil M; Günthard HF;
J Acquir Immune Defic Syndr; 2013 Jan; 62(1):28-35. PubMed ID: 23018371
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy.
Dahl V; Lee E; Peterson J; Spudich SS; Leppla I; Sinclair E; Fuchs D; Palmer S; Price RW
J Infect Dis; 2011 Dec; 204(12):1936-45. PubMed ID: 22021620
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
[TBL] [Abstract][Full Text] [Related]
8. Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.
Joseph SB; Kincer LP; Bowman NM; Evans C; Vinikoor MJ; Lippincott CK; Gisslén M; Spudich S; Menezes P; Robertson K; Archin N; Kashuba A; Eron JJ; Price RW; Swanstrom R
Clin Infect Dis; 2019 Sep; 69(8):1345-1352. PubMed ID: 30561541
[TBL] [Abstract][Full Text] [Related]
9. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
[TBL] [Abstract][Full Text] [Related]
10. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A
Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350
[TBL] [Abstract][Full Text] [Related]
12. Correlates of HIV RNA concentrations in cerebrospinal fluid during antiretroviral therapy: a longitudinal cohort study.
Livelli A; Vaida F; Ellis RJ; Ma Q; Ferrara M; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Grant I; Letendre SL;
Lancet HIV; 2019 Jul; 6(7):e456-e462. PubMed ID: 31208949
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
[TBL] [Abstract][Full Text] [Related]
14. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
[TBL] [Abstract][Full Text] [Related]
15. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
[TBL] [Abstract][Full Text] [Related]
16. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
18. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.
Arvidson N; Gisslén M; Albert J; Brandin E; Svennerholm B; Fuchs D; Hagberg L
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):711-5. PubMed ID: 15307916
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.
Rawson T; Muir D; Mackie NE; Garvey LJ; Everitt A; Winston A
J Infect; 2012 Sep; 65(3):239-45. PubMed ID: 22522289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
